Tag: GW Pharma

Did GW Pharma Sell Out Too Low?

You’re reading a copy of this week’s edition of the New Cannabis Ventures weekly newsletter, which we have been publishing since October 2015. The newsletter includes unique insight to...
- February 7th, 2021 at 10:56 am

GW Pharma to Be Acquired for $220 Per Share

GW Pharmaceuticals plc, Creating an Innovative, High-Growth, Global Biopharma Leader Adds high-growth commercial franchise to Neuroscience portfolio with Epidiolex®, the first and only FDA-approved prescription cannabidiol medicine and a...
- February 3rd, 2021 at 8:08 am

A Massive Swing in Cannabis Sector Sentiment

You’re reading a copy of this week’s edition of the New Cannabis Ventures weekly newsletter, which we have been publishing since October 2015. The newsletter includes unique insight to...
- August 9th, 2020 at 10:56 am

FDA Expands GW Pharma’s Epidiolex Label

FDA Approves EPIDIOLEX® (cannabidiol) Oral Solution to Treat Seizures Associated with Tuberous Sclerosis Complex – Age-range for all EPIDIOLEX indications expanded to include patients one year of age and...
- August 3rd, 2020 at 7:35 am

Cannabis Earnings Season Revs Into High Gear

The Public Cannabis Company Revenue & Income Tracker, managed by New Cannabis Ventures, ranks the top revenue producing cannabis stocks that generate industry sales of more than US$7.5 million per...
- May 18th, 2020 at 10:58 am

This Cannabis Stock Catalyst is Kicking In

You’re reading a copy of this week’s edition of the New Cannabis Ventures weekly newsletter, which we have been publishing since October 2015. The newsletter includes unique insight to...
- May 17th, 2020 at 10:55 am

GW Pharma Generates $109 Million Revenue in Q4

GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2019 Financial Results and Operational Progress Total revenue of $109.1 million for the fourth quarter and $311.3 million for the full...
- February 25th, 2020 at 4:24 pm